Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$1,696 Mln
P/E Ratio
--
P/B Ratio
1.66
Industry P/E
--
Debt to Equity
0.02
ROE
-0.1 %
ROCE
-9.75 %
Div. Yield
0 %
Book Value
18.94
EPS
-1.28
CFO
$-118.67 Mln
EBITDA
$-180.42 Mln
Net Profit
$-154.50 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Janux Therapeutics Inc (JANX)
| -44.55 | -3.23 | -26.89 | -41.27 | 30.14 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Janux Therapeutics Inc (JANX)
| 392.48 | -18.53 | -33.25 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients with cancer. Its... clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. Address: 10955 Vista Sorrento Parkway, San Diego, CA, United States, 92130 Read more
President, CEO & Director
Dr. David Alan Campbell Ph.D.
President, CEO & Director
Dr. David Alan Campbell Ph.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Janux Therapeutics Inc (JANX) stood at $ 1,062 Mln as on 31-Dec-24
The share price of Janux Therapeutics Inc (JANX) is $29.69 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Janux Therapeutics Inc (JANX) has given a return of 30.14% in the last 3 years.
Janux Therapeutics Inc (JANX) has a market capitalisation of $ 1,696 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Janux Therapeutics Inc (JANX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Janux Therapeutics Inc (JANX) and enter the required number of quantities and click on buy to purchase the shares of Janux Therapeutics Inc (JANX).
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. Address: 10955 Vista Sorrento Parkway, San Diego, CA, United States, 92130
The CEO & director of Dr. David Alan Campbell Ph.D.. is Janux Therapeutics Inc (JANX), and CFO & Sr. VP is Dr. David Alan Campbell Ph.D..
There is no promoter pledging in Janux Therapeutics Inc (JANX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Janux Therapeutics Inc (JANX) | Ratios |
|---|---|
|
Return on equity(%)
|
-10.09
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-651.62
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Janux Therapeutics Inc (JANX) was $0 Mln.
$1.00
(
